Dense Deposit Disease: Eculizumab

Department of Health written question – answered on 3rd November 2016.

Alert me about debates like this

Photo of Andrea Jenkyns Andrea Jenkyns Conservative, Morley and Outwood

To ask the Secretary of State for Health, what recent discussions he has had with NHS England on the effectiveness of eculizumab for the treatment of dense deposit disease.

Photo of Andrea Jenkyns Andrea Jenkyns Conservative, Morley and Outwood

To ask the Secretary of State for Health, what recent discussions he has had with the Clinical Priorities Advisory Group on the funding of eculizumab for the treatment of dense deposit disease.

Photo of David Mowat David Mowat The Parliamentary Under-Secretary of State for Health

Eculizumab is not a licensed treatment for Dense Deposit Disease and well-constructed clinical trials on effectiveness are yet to be carried out. A new policy proposition for its use in treating the disease before a patient has had a kidney transplant will be considered during 2016/17.

There is a published policy on use of this drug for the prevention of recurrence after a patient has had a transplant. A policy on the treatment of C3 glomerulopathy that occurs after a kidney transplant will be considered by the Clinical Priorities Advisory Group (CPAG) at its next meeting. The CPAG reviews both patient benefits and cost considerations when making recommendations.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.